Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04144140 · ClinicalTrials.gov registry record · Phase 1
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
A Phase 1 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT04144140 is a Phase 1 study that was terminated before completion, run by Eisai. The registered enrollment target is 24 participants.
The verdict
NCT04144140, a Phase 1 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
Interventions
- DRUG E7766
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-02-24 |
| Est. Completion | 2022-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04144140
The ClinicalTrials.gov registry entry for NCT04144140 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E7766 is the first listed.
NCT04144140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04144140 about?
NCT04144140 is a clinical study titled "Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101". This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intratumorally in participants with advanced solid tumors or lymphomas.
What is the current status of trial NCT04144140?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-02-24. Estimated completion is 2022-07-26.
What interventions are being tested in trial NCT04144140?
The interventions under investigation include: E7766 (DRUG).
Who is sponsoring clinical trial NCT04144140?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.